Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

Planned uses include a Phase 3 acne trial of denifanstat and funding TVB-3567 through Phase 2 topline results.

Rhea-AI Summary

Sagimet Biosciences (SGMT) closed its underwritten offering of Series A common stock and pre-funded warrants, raising approximately $115.0 million in gross proceeds.

The offering included 8,750,010 shares at $10.00 each and pre-funded warrants to purchase 2,750,010 shares at $9.9999 per warrant. The warrants are immediately exercisable at $0.0001 per share. Gross proceeds exclude underwriting discounts, commissions and other offering expenses. Sagimet intends to use net proceeds alongside existing funds for a Phase 3 acne trial of denifanstat, its pre-launch activities, TVB-3567 through Phase 2 topline results, and its topical FASN inhibitor program through an investigational new drug application submission.

4 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointOffering closed with approximately $115.0 million in gross proceeds raised by Sagimet. 19% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to fund a Phase 3 denifanstat acne trial and denifanstat pre-launch activities.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to fund TVB-3567 through Phase 2 topline results.
• Minor point. Forward-looking: it has not happened yet and may not happen.Sagimet plans to advance its topical FASN inhibitor program through investigational new drug application submission.

Negative

• Major pointIssuance of 8,750,010 Series A common shares at $10.00 each dilutes existing holders.
• Minor pointPre-funded warrants cover 2,750,010 shares at $9.9999 per warrant, immediately exercisable at $0.0001 per share.
• Minor pointGross proceeds are subject to underwriting discounts, commissions and other offering expenses.

News Explained

Sagimet sold the shares itself; issuing those shares raises the share count, and exercising its immediately exercisable pre-funded warrants can add further shares, reducing existing holders’ ownership percentages.

Key Figures

Common shares offered: 8,750,010 shares at $10.00 per share Pre-funded warrants: 2,750,010 warrants at $9.9999 per warrant Warrant exercise price: $0.0001 per share +1 more

Common shares offered

8,750,010 shares at $10.00 per share

Series A common stock

Pre-funded warrants

2,750,010 warrants at $9.9999 per warrant

Each warrant is exercisable for one Series A common share

Warrant exercise price

$0.0001 per share

Pre-funded warrants are exercisable immediately

Gross proceeds

Approximately $115.0 million

Before underwriting discounts, commissions and other offering expenses

Previous Offering Reports

1 past event · Latest: Sep 30

Same Type 1 event

1. Sep 30

   Offering pricing

   24h Move

   +6.0%

   Set the share and warrant terms for the offering that this announcement reports as closed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten offering, pre-funded warrants, shelf registration statement, prospectus supplement

4 terms

underwritten offering financial

"closing of its previously announced underwritten offering"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

pre-funded warrants financial

"in lieu of shares of Series A common stock, pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A prospectus supplement relating to the offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering were sold by Sagimet.

The financing was led by Commodore Capital, with participation from new and existing institutional investors, including RA Capital Management, Spruce Street Capital, BVF Partners L.P., Aberdeen Investments, Columbia Threadneedle Investments, Affinity Asset Advisors, LLC, and Woodline Partners LP.

Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. acted as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co., Jones and Clear Street acted as co-lead managers for the offering.

Sagimet intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, pre-launch activities for denifanstat, TVB-3567 through Phase 2 topline results, advancement of its topical formulation FASN inhibitor program to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses.

A shelf registration statement on Form S-3 (File No. 333-281582) relating to these securities was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on August 26, 2024. A prospectus supplement relating to the offering, and the accompanying prospectus, were filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, without limitation, statements regarding the intended use of the proceeds from the offering. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the offering and other risks and uncertainties described under the heading “Risk Factors” in documents Sagimet files from time to time with the SEC. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause Sagimet’s actual results to differ may emerge from time to time, and it is not possible for Sagimet to predict all of them. Sagimet undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Sagimet Biosciences raise in its completed SGMT offering?

Sagimet raised approximately $115.0 million in gross proceeds, before underwriting discounts, commissions and other offering expenses. All securities in the offering were sold by Sagimet.

What were the share and pre-funded warrant prices in Sagimet Biosciences' offering?

The offering priced 8,750,010 Series A common shares at $10.00 each and pre-funded warrants covering 2,750,010 shares at $9.9999 per warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately.